Change in willingness to COVID-19 vaccination in China: Two online surveys during the pandemic

Ninghua Huang1,2 | Chao Wang2,3 | Bingfeng Han1 | Tianshuo Zhao1 | Bei Liu3 | Linyi Chen1 | Mingzhu Xie3 | Hui Zheng1 | Sihui Zhang2 | Yu Wang2 | Du Juan3 | YaQiong Liu1 | QingBin Lu1,2,3,4 | Fuqiang Cui1,2,3,4

1Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, China
2Vaccine Research Center, School of Public Health, Peking University, Beijing, China
3Global Center for Infectious Disease and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China
4Department of Global Health, School of Public Health, Peking University, Beijing, China

Correspondence
Fuqiang Cui, Professor and Head of Department of Laboratorial Science and Technology & Vaccine Research Center, School of Public Health, Peking University, Beijing, China. Email: cuifuq@bjmu.edu.cn

Funding information
Peking University; Natural Science Foundation of Beijing Municipality; Peking University Health Science Center; Ministry of Science and Technology of the People’s Republic of China

Abstract

Objective: As the variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, periodic vaccine booster immunization may become a normal policy. This study investigated the changes and factors associated with vaccination intentions in various epidemic situations, which can provide suggestions for the construction and modification of routine vaccination program strategies.

Methods: Two cross-sectional online surveys were conducted in January and June of 2021. The willingness and confidence of the coronavirus disease 2019 (COVID-19) vaccination were measured following propensity score matching (PSM) treatment. The difference in the willingness for COVID-19 Vaccination in the two surveys was analyzed by single or multi-factor analyses.

Results: The willingness to accept the SARS-CoV-2 vaccine was higher in the second survey than that in the first survey (90.5% vs. 66.6%, p < 0.001). Concerns about the vaccine’s safety declined (71.0% vs. 47.6%, p < 0.001), but concerns about the efficacy increased (22.4% vs. 30.9%, p < 0.001). Confidence in the SARS-CoV-2 vaccine had an important impact on the increased uptake willingness (odds ratio = 3.19, 95% confidence interval: 2.23–4.58, p < 0.001).

Conclusions: There has been a significant increase in attitudes towards the SARS-CoV-2 vaccine which was associated with higher vaccine confidence. Vaccine effectiveness received more concerns from respondents rather than safety after nearly 6 months' utilization of the SARS-CoV-2 vaccine. It indicates that aggressive communication and timely disclosure of vaccine data can build vaccine confidence.

Keywords
propensity score matching, SARS-CoV-2 vaccine, vaccine acceptance, vaccine confidence, vaccine willingness
The timeline of surveys, vaccination and coronavirus disease 2019 (COVID-19) cases.
Trust in the SARS-CoV-2 vaccine was assessed by the extent to which people agree with the importance, effectiveness, and safety of the vaccine. Trust in the delivery system was measured based on confidence in healthcare providers, professional institutes, and vaccine manufacturers. Total trust in vaccines and delivery systems was scored from 3 to 9 on a scale of agree (trust score of 5) and disagree (trust score of 4). Confidence in government was measured by a question that was categorized as agree, uncertain or outright disagree and divided into agree and disagree (uncertain and disagree).

### 2.3 Vaccination willingness

Participants were asked whether they were willing to vaccinate with SARS-CoV-2 vaccine. If they answered that they were very looking forward to or wanted to be vaccinated, it was defined as with vaccination willingness.

### 2.4 Statistical analysis

Categorical variables are reported as absolute and relative frequencies, and the Chi-square test is used to determine discrepancies in their distributions. We utilized logistic regression to obtain an association of confidence (including vaccines, delivery, and government), anxiety state, degree of risk perception with vaccination willingness. The general characteristics including age, gender, education level, profession, and residence were invoked as covariant. We maintained these variables and then examined the impact of each component separately. Odds ratio (OR) and the 95% confidence interval (CI) were estimated.

To minimize potential confounding bias arising from differences in baseline characteristics, propensity scores were calculated and matched to balanced covariates for the first and second surveys. Propensity score matching (PSM) is a statistical technique that helps to strengthen causal arguments in quasi-experimental and observational studies by reducing selection bias. The first and second survey groups were paired 1:1 based on propensity scores from the nearest neighbor matching method. SPSS (version 22.0, IBM) was used for data cleaning and statistical analysis. PSM was conducted using R for statistical computing software (version 4.0.2; R Foundation for Statistical Computing, Vienna Austria). The difference was statistically significant at \( p < 0.05 \).

### 2.5 Ethical approval

This study was approved by Peking University Institutional Review Board (IRB00001052-210001); exemption for informed consent was granted.

### 3 RESULTS

#### 3.1 Socio-demographic characteristics of the sample

A total of 2579 questionnaires were received at the second survey. Ten were eliminated owing to IP addresses, and 67 were excluded due to quality issues or logical errors. Finally, the 2502 questionnaires were involved for analyses, with a 97.0% valid response rate. Participants came from mainland China, including South China (561, 22.4%), North China (546, 21.8%), and East China (502, 20.1%) as the top three regions.

In this survey, the inactivated vaccine had the highest vaccination rate among those who had had vaccinations (1911/2096, 91.1%), followed by the recombinant protein vaccine (83/2096, 3.9%) and the adenovirus vaccine (27/2096, 1.29%). A small percentage of the population was likewise unaware of the vaccine they had taken (75/2096, 3.58%).

#### 3.2 Comparison between two cross-sectional surveys

The demographic characteristics of the first survey group \((n = 8743)\) and the second survey group \((n = 2502)\) were shown in Table 1. Before PSM operation, there were significant differences in the following variables between the two surveys: region, sex, age, education level, and district \((p < 0.050)\). After PSM, participants in the first \((n = 1992)\) and the second \((n = 1992)\) groups had similar demographic characteristics (Table 1). There were no statistically significant differences in demographic characteristics between respondents from the two surveys \((SMD < 0.1, p > 0.05)\).

The participants from the second survey had a relatively higher vaccine willingness in accepting SARS-CoV-2 vaccines \((66.6\% \text{ vs. } 90.5\%, p < 0.001)\) than in the first survey \((p < 0.001)\) (Table 2). Trust in vaccines, delivery, and governance were also significantly increased at the second survey comparing to the first \((p < 0.001)\).

#### 3.3 Willingness of COVID-19 vaccination

Participants who were hesitant or unsure about receiving the vaccination were asked to explain their rejection or reluctance. The results show that the safety and effectiveness of vaccines were among the top two concerns in both surveys (Table 3). Compared with the first survey, concerns about the vaccine's safety declined \((71.0\% \text{ vs. } 47.6\%, p < 0.001)\), while concerns about the vaccine's effectiveness grew significantly \((22.4\% \text{ vs. } 30.9\%, p < 0.001)\) in the second survey.
3.4 | Confidence in COVID-19 vaccination

There was no statistical difference in an increased willingness to COVID-19 vaccination among people of different gender, ages, education, residence, and geographical location (Table 4). Increased confidence in the SARS-CoV-2 vaccines had an important impact on the increased willingness, which was statistically significant (OR = 3.19, 95% CI: 2.23–4.58, p < 0.001). However, the changes of
Confidence in vaccination institutions \( (p = 0.084) \) and the government \( (p = 0.067) \) had no statistically significant impact on the increased willingness to COVID-19 vaccination.

### 4 | DISCUSSION

We conducted two online surveys in mainland China, with data from the first survey (January 10–January 22, 2021) and the second survey (June 11–June 29, 2021). We found that attitudes toward vaccination became more positive, with increased confidence in vaccine trust, delivery system trust, and government trust in the second survey compared to the first. The first survey was conducted during the first phase of the SARS-CoV-2 vaccine immunization strategy in China.\(^\text{12}\) The second survey was during the third phase of China's immunization wave, and the vaccination population covers all people over 3 years of age. As of June 29, 2021, the total number of COVID-19 patients in China was 91,834, and the entire immunization coverage for the SARS-CoV-2 vaccine was 85.16%.\(^\text{13}\) The gap in vaccination willingness between the two surveys can be interpreted in the context of different epidemics. The following reasons might be mostly responsible for the increase in vaccination willingness. First, the government was actively promoting the public's scientific understanding that the overall benefits of vaccination far outweigh the risk of the SARS-CoV-2 vaccine. Second, vaccination convenience was largely improved as vaccine supply had risen and immunization locations had been distributed more rationally. Finally, some sporadic outbreaks occurred in different areas of China between the first and second surveys.\(^\text{14,15}\) The emergence of transmissible outbreaks had increased public awareness of the greater risk of contracting viruses than vaccine side effects, which contributes to their decisions to vaccinate.

The findings of both surveys suggested that many people expressed doubts or worries about the effectiveness and safety of vaccination. However, the focus of public confidence in the vaccine was not consistent at different phases. The focus of public concerns at initial phase of vaccination was more focused on the safety of the vaccine. According to the reasons for refusal and hesitation reported by participants in the first survey, people expressed more doubts or concerns about the safety of vaccination than other reasons. This finding is consistent with those of prior research.\(^\text{16–20}\) However, compared to the first survey, the main concern for vaccine willingness in the second survey converted to effectiveness rather than the safety of the vaccine. This may be due to the rapid pace of current vaccine research, the short time to market, and the special emergency use procedures, all of which have led to a lack of public confidence in vaccine safety. Once the vaccine was administered on a large scale and safety has been proven, the lack of data on vaccine effectiveness and long-term sustainability ultimately leads to a decline in safety concerns and a rise in concerns about vaccine effectiveness.

| TABLE 2 | Analysis of willingness and vaccine confidence between two surveys after PSM treatment |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Characteristics                                      | First survey \( n (%) \) | Second survey \( n (%) \) | \( p \) value |
| Total willingness                                    |                                |                                |                |
| No                                                   | 176 (8.8%)                     | 49 (2.5%)                      | <0.001         |
| Unsure                                               | 489 (24.5%)                    | 141 (7.1%)                     |                |
| Yes                                                  | 1327 (66.6%)                   | 1802 (90.5%)                   |                |
| Vaccine trust                                        |                                |                                |                |
| No                                                   | 639 (32.1%)                    | 287 (14.4%)                    | <0.001         |
| Yes                                                  | 1353 (67.9%)                   | 1705 (85.6%)                   |                |
| Delivery trust                                       |                                |                                |                |
| No                                                   | 419 (21%)                      | 183 (9.2%)                     | <0.001         |
| Yes                                                  | 1573 (79%)                     | 1809 (90.8%)                   |                |
| Government trust                                     |                                |                                |                |
| No                                                   | 368 (18.5%)                    | 156 (7.8%)                     | <0.001         |
| Yes                                                  | 1624 (81.5%)                   | 1836 (92.2%)                   |                |

Abbreviation: PSM, propensity score matching.

| TABLE 3 | Reasons for SARS-CoV-2 vaccine refusal or hesitancy in two surveys |
|---------|---------------------------------------------------------------|----------------|----------------|--------|
| Reasons | The first survey \( n (%) \)                                | The second survey \( n (%) \) | \( p \)-value |
| Worry about the SARS-CoV-2 vaccine safety            | 2041 (71.0%)                     | 111 (47.6%)                | <0.001 |
| Low effectiveness of the SARS-CoV-2 vaccine          | 644 (22.4%)                      | 72 (30.9%)                 | 0.01   |
| The leaders and colleagues do not take               | 149 (5.2%)                       | 9 (3.9%)                   | 0.44   |
| The relatives and friends do not support the SARS-CoV-2 vaccine | 91 (3.2%)                      | 8 (3.4%)                   | 0.85   |
| Healthy enough and no need to receive the SARS-CoV-2 vaccine | 214 (7.5%)                      | 21 (9.0%)                  | 0.37   |
| It's safe in the country and no need to be vaccinated at this moment | 528 (18.9%)                     | 37 (15.9%)                 | 0.38   |
| Other reasons                                       | 651 (22.7%)                      | 92 (39.5%)                 | <0.001 |

Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
These two surveys sought to identify predictors of willingness to take the SARS-CoV-2 vaccine. According to the majority of previous studies, sociodemographic characteristics were significantly associated with the intention to receive the SARS-CoV-2 vaccine.\textsuperscript{21–24} For instance, age,\textsuperscript{8,22,25–29} income,\textsuperscript{17,30–32} and education are all important factors that associate with the willingness to vaccination. However, our results did not provide comparable findings. This finding also implies that socio-demographic factors did not have a significant impact on vaccination intentions. Furthermore, socio-demographic variables are at most a collection of possible reasons for certain behaviors and can never fully account for them without additional research.

In our study, trust in the vaccine had the greatest impact on vaccination willingness, which was likely due to the rapid introduction of the SARS-CoV-2 vaccine, which had a greater impact on vaccination intention compared to other established vaccine products. In most studies, vaccine confidence was identified as having a positive impact on vaccination intention and vaccination coverages, including trust in the health system, government, and vaccine products.\textsuperscript{18,19,30,33}

With the advent of the SARS-CoV-2 variants, the question of booster vaccination and the willingness of elderly persons to be vaccinated has become especially pressing. The duration of the epidemic boosts the public’s risk perception of the SARS-CoV-2 vaccine, resulting in increased vaccination intentions. Health authorities, and regulatory agencies use health communication techniques on various media platforms to ensure that individuals are aware of their perceived risk of disease and positively promote vaccination. Moreover, timely disclosure of vaccine information is important for vaccination intentions, including data on vaccine effectiveness, safety, and persistence. Timely disclosure of data on vaccine durability and validity in the real world plays an important role in vaccine confidence, especially at a time when booster and elderly vaccination rates are being increased, which allows individuals to build vaccine trust and make informed decisions with confidence in the information they receive.

When considering the findings of this study, there are still some limitations of this study as follows. First, there are limitations in population representation. Although this study was designed to reflect the socio-demographic characteristics of the entire Chinese population, there was no random sampling in the selection of survey participants. In addition, this study is an internet-based survey, the sample size of older adults is relatively small due to difficulties in accessing the internet. Second, potential important confounders may not have been adjusted in this study. Information on risk perception, other potential confounders such as income, and health status were not included in this study due to data limitations. Therefore, it remains possible that the relationship between the variable factors included in the study and vaccine hesitancy is spurious. Finally, this study was an observational study, and therefore a causal relationship between explanatory and outcome variables could not be demonstrated.

### 5 | CONCLUSIONS

This study discovered a significant increase in willingness to get the COVID-19 vaccination during pandemics, and such change was connected with higher public trust in the vaccine, regardless of socio-demographic characteristics. Compared to the first survey,
respondents in the second survey were more concerned about vaccine effectiveness rather than safety. To ensure that vaccination can be regularized in the context of different epidemics, it is crucial to maintain public confidence in vaccines, and vaccine data must be actively communicated and disclosed in a timely manner.

AUTHOR CONTRIBUTIONS
Conceptualization: Fuqiang Cui, Chao Wang, and Ninghua Huang. Methodology: Bingfeng Han, Chao Wang, and Ninghua Huang. Investigation: Tianshuo Zhao, Bei Liu, Linyi Chen, Mingzhu Xie, Hui Zheng, Shihui Zhang, Yu Wang, Juan Du, YaQiong Liu, and QingBin Lu. Writing—Original draft preparation: Bingfeng Han and Ninghua Huang. Writing—review and editing: Fuqiang Cui, QingBin Lu, Chao Wang, and Ninghua Huang. All authors have read and agreed to the published version of the manuscript. N.H. and C.W. contributed equally to this study.

ACKNOWLEDGEMENTS
This study was supported by the National Key Research and Development Program of China (2021YFC2301604), Fundamental Research Funds for the Central Universities and Peking University Health Science Center (BMU2022XY030), Peking University Medicine Fund of Fostering Young Scholars’ Scientific & Technological Innovation (BMU2021PY005), Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation (L202007) and Global Center for Infectious Disease and Policy Research & Global Health and Infectious Diseases Group, Peking University.

CONFLICTS OF INTEREST
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
QingBin Lu https://orcid.org/0000-0002-2804-0827

REFERENCES
1. Wang B, Goh YS, Fong SW, et al. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The Lancet Regional Health - Western Pacific. 2021;5:100276. doi:10.1016/j.lanwpc.2021.100276
2. Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108-2110. doi:10.1038/s41591-021-01575-4
3. The State Council Information Office, P.R.C. Press conference held on situation regarding strict prevention and control of COVID-19 epidemic. June 24, 2022. http://www.gov.cn/xinwen/gwyfflkjz2023/index.htm
4. Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022;185(12):2103-2155. doi:10.1016/j.cell.2022.04.033
5. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022. doi:10.1038/s41586-022-04980-y
6. Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nat Med. 2022. doi:10.1038/s41591-022-01855-7
7. Biasio LR, Bonacorsi G, Lorini C, et al. Italian adults’ likelihood of getting COVID-19 vaccine: a second online survey. Vaccines (Basel). 2021;9(3). doi:10.3390/vaccines9030268
8. Wang C, Han B, Zhao T, et al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study, Vaccine. 2021;39(21):2833-2842. doi:10.1016/j.vaccine.2021.04.020
9. Szilagy PG, Thomas K, Megha D, et al. National trends in the US public’s likelihood of getting a COVID-19 Vaccine-April 1 to December 8, 2020. JAMA. 2020;325(4):396-398. doi:10.1001/jama.2020.26419
10. Fridman A, Gershon R, Gneezy A. COVID-19 and vaccine hesitancy: a longitudinal study, PLoS One. 2021;16(4):e0250123. doi:10.1371/journal.pone.0250123
11. Randolph JJ, et al. A step-by-step guide to propensity score matching in R. PARE. 2014;19:Article 18.
12. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2021. https://covid19.who.int/
13. China NHCC. COVID-19 vaccination status. 2022. http://www.nhc.gov.cn/xcs/yqzqk/202106/74ed0aa148744960988030bf6a3186da.shtml
14. Li WY, Du ZC, Wang Y, et al. Epidemiological characteristics of local outbreak of COVID-19 caused by SARS-CoV-2 Delta variant in Liwan district, Guangzhou. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(10):1763-1768. doi:10.3760/cma.j.cn112338-20210613-00472
15. Zhao WH, Ma Y, Hang H, et al. Epidemiological characteristics of three local epidemics of COVID-19 in Guangzhou. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(12):2088-2095. doi:10.3760/cma.j.cn112338-20210728-00592
16. Gallant AJ, Brown Nicholls LA, Rasmussen S, et al. Changes in attitudes to vaccination as a result of the COVID-19 pandemic: a longitudinal study of older adults in the UK. PLoS One. 2021;16(12):e0261844. doi:10.1371/journal.pone.0261844
17. Kreps S, Prasad S, Brownstein JS, et al. Factors associated with US adults’ likelihood of accepting COVID-19 vaccination. JAMA Netw Open. 2020;3(10):e2025594. doi:10.1001/jamanetworkopen.2020.25594
18. Sharun K, Rahman CKF, Haritha CV, et al. Covid-19 vaccine acceptance: beliefs and barriers associated with vaccination among the general population in India. J Exp Biol Agric Sci. 2020;8(suppl 1):S210-S218. doi:10.18006/2020.8(Spl-1-SARS-CoV-2).S210.S218
19. Callaghan T, Moghaderi A, Lueck JA, et al. Correlates and disparities of intention to vaccinate against COVID-19. Soc Sci Med. 2021;272:113638. doi:10.1016/j.socscimed.2021.113638
20. Taylor S, Landry CA, Paluszek MM, et al. A proactive approach for managing COVID-19: the importance of understanding the motivational roots of vaccination hesitancy for SARS-CoV2. Front Psychol. 2020;11:575950. doi:10.3389/fpsyg.2020.575950
21. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: implications for public health communications. Lancet Regional Health - Eur. 2021;1:100012. doi:10.1016/j.lanpre.2020.100012
22. Daly M, Robinson E. Willingness to vaccinate against COVID-19 in the U.S.: representative longitudinal evidence from April to October 2020. Am J Prev Med. 2021;60(6):766-773. doi:10.1016/j.amepre.2021.01.008
23. AlShurman BA, Khan AF, Mac C, et al. What demographic, social, and contextual factors influence the intention to use COVID-19 vaccines: a scoping review. *Int J Environ Res Pub Health*. 2021;18(17). doi:10.3390/ijerph18179342

24. Shakeel CS, Mujeeb AA, Mirza MS, et al. Global COVID-19 vaccine acceptance: a systematic review of associated social and behavioral factors. *Vaccines (Basel)*. 2022;10(1):110. doi:10.3390/vaccines10010110

25. Kabamba Nzaji M, Ngombe LK, Mwamba GN, et al. Acceptability of vaccination against COVID-19 among healthcare workers in the Democratic Republic of the Congo. *Pragmat Obs Res*. 2020;11:103-109. doi:10.2147/POR.S271096

26. Gagneux-Brunon A, Detoc M, Bruel S, et al. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey. *J Hosp Infect*. 2021;108:168-173. doi:10.1016/j.jhin.2020.11.020

27. Kourlaba G, Kourkouni E, Maistreli S, et al. Willingness of Greek general population to get a COVID-19 vaccine. *Glob Health Res Policy*. 2021;6(1):3. doi:10.1186/s41256-021-00188-1

28. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated? *Vaccine*. 2020;38(42):6500-6507. doi:10.1016/j.vaccine.2020.08.043

29. Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. *Vaccines*. 2020;8(3):482.

30. Fisher KA, Bloomstone SJ, Walder J, et al. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. *Ann Intern Med*. 2020;173(12):964-973. doi:10.7326/m20-3569

31. Al-Mohaithef M, Padi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. *J Multidiscip Healthc*. 2020;13:1657-1663. doi:10.2147/Jmdh.S276771

32. Okubo R, Yoshioka T, Ohfuji S, et al. COVID-19 vaccine hesitancy and its associated factors in Japan. *Vaccines*. 2021;9(6). doi:10.3390/vaccines9060662

33. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol*. 2020;35(8):775-779. doi:10.1007/s10654-020-00671-y

**How to cite this article:** Huang N, Wang C, Han B, et al. Change in willingness to COVID-19 vaccination in China: Two online surveys during the pandemic. *J Med Virol*. 2022;94:5271-5278. doi:10.1002/jmv.28004